Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now shown, replacing Revision: v3.3.3. No study content or details were modified.
    Difference
    0.1%
    Check dated 2026-01-14T02:14:56.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Added a Locations section listing Massachusetts sites for the study and updated the page revision to v3.3.3. Removed the older Massachusetts Locations entry and the HHS Vulnerability Disclosure link in the prior revision.
    Difference
    0.2%
    Check dated 2025-12-23T20:40:18.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The study locations were updated to three sites, adding Dana-Farber Cancer Institute in Boston, MA. The prior note indicating two locations was removed.
    Difference
    0.4%
    Check dated 2025-12-09T13:46:28.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Footer revision label updated to v3.3.2; the previous v3.2.0 label was removed. This reflects a system or UI update rather than changes to the study content.
    Difference
    0.1%
    Check dated 2025-11-25T10:08:32.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The government funding/operating status notice previously displayed on the page has been removed. This is an administrative change not affecting the clinical trial data or participant information.
    Difference
    0.4%
    Check dated 2025-11-18T03:27:03.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The changes are limited to formatting and layout without any alterations to core study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T18:36:59.000Z thumbnail image

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.